Articles From: NEMUS Bioscience Is Now Quoted on the OTC Bulletin Board Under the Ticker Symbol of “NMUS” to NeoStem Announces USAN Approval of Generic Name 'Eltrapuldencel-T' for Investigational Patient-Specific Targeted Cancer Immunotherapy


NEMUS Bioscience, Inc. a Nevada corporation (the “Company”), announced that its common stock is now eligible for quotation on the OTC Bulletin Board under the ticker symbol (NMUS). NEMUS completed a reverse merger with Load Guard Logistics, Inc. (“LGL”), a Nevada corporation, on October 31, 2014.
Sign-up for NEMUS Bioscience Is Now Quoted on the OTC Bulletin Board Under the Ticker Symbol of “NMUS” investment picks
2014/11/4
NEMUS, a California corporation, announced that it has completed a reverse merger with Load Guard Logistics, Inc. (“LGL”), a Nevada corporation, on October 31, 2014 pursuant to that certain agreement and plan of merger dated October 17, 2014 by and among LGL, Nemus Acquisition Corp., NEMUS and Nemus Bioscience, Inc. (the “Merger Agreement”). NEMUS survives the merger as a wholly-owned subsidiary of LGL.
Sign-up for NEMUS Completes Reverse Merger With Load Guard Logistics, Inc. investment picks
COSTA MESA, Calif., Dec.
Sign-up for NEMUS to Move Forward With Cannabinoid-Based Therapy for Open-Angle Glaucoma investment picks
LANSING, Mich.
Sign-up for Neogen acquires assets of its Chinese distributor investment picks
LANSING, Mich.
Sign-up for Neogen names COO investment picks
LANSING, Mich.
Sign-up for Neogen reports 26% increase in net income investment picks
Additional test for susceptibility in certain types of lymphoma FT.
Sign-up for NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia investment picks
Company Raises Full-Year Revenue Guidance to $85.0 to $86.5 Million FT.
Sign-up for NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014 investment picks
STOCKHOLM, Sweden, Jan.
Sign-up for Neonode Awarded All-In-One PC Deal Including Prepayment With a Global Tier ONE PC OEM investment picks
STOCKHOLM, Sweden, Jan.
Sign-up for Neonode Signs Technology Development Agreement With an Additional Global Tier One Printer OEM investment picks
SANTA CLARA, Calif., Oct.
Sign-up for Neonode Signs Technology Development Agreement With Global Tier One Printer OEM investment picks
STOCKHOLM, Sweden, Dec.
Sign-up for Neonode to Demonstrate Cutting Edge Touch Technologies at CES 2015 investment picks
STOCKHOLM, Sweden, Nov.
Sign-up for Neonode(R) Reports Results for Quarter Ended September 30, 2014 investment picks
STOCKHOLM, Sweden, Dec.
Sign-up for Neonode(R) to Present at Needham Annual Growth Conference on January 15, 2015 investment picks
SANTA CLARA, Calif., Oct.
Sign-up for Neonode(R) to Report Third Quarter 2014 Results on November 6, 2014 investment picks
NeoPhotonics Corporation (NYSE:NPTN), a leading designer and manufacturer of photonic integrated circuits, or PIC, based modules and subsystems for bandwidth-intensive, high speed communications networks, today announced that it has entered into a definitive purchase agreement with EMCORE Corporation (NASDAQ:EMKR) under which NeoPhotonics will purchase the assets of EMCORE’s tunable laser and transceiver product lines for approximately $17.5 million, which consists of $15.0 million and a working capital and inventory adjustment of approximately $2.5 million.
Sign-up for NeoPhotonics Announces Acquisition of EMCORE’s Narrow Linewidth Tunable Laser Product Line investment picks
NeoPhotonics Corporation (NYSE:NPTN), today announced that it has completed the acquisition of the tunable laser product lines of EMCORE Corporation (NASDAQ: EMKR) for approximately $17.5 million.
Sign-up for NeoPhotonics Completes Acquisition of EMCORE’s Narrow Linewidth Tunable Laser Product Line investment picks
NeoPhotonics Corporation (NYSE:NPTN), a leading designer and manufacturer of hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high speed communications networks, reported that in connection with the completion of its acquisition of the Narrow Linewidth Tunable Laser Product Line of EMCORE Corporation, the company granted special inducement equity awards under the NeoPhotonics 2011 Inducement Award Plan to retain certain former Emcore employees (23 in total) as employees of the NeoPhotonics group.
Sign-up for NeoPhotonics Reports Equity Award Inducement Grants to Employees Hired with the Acquisition of Emcore’s Narrow Linewidth Tunable Laser Product Line investment picks
NeoPhotonics Corporation (NYSE: NPTN), a leading designer and manufacturer of photonic integrated circuits, or PIC, based optoelectronic modules and subsystems for bandwidth-intensive, high speed communications networks, today announced financial results for its third quarter ended September 30, 2014.
Sign-up for NeoPhotonics Reports Third Quarter Financial Results and Outlook for Fourth Quarter 2014 investment picks
NeoPhotonics Corporation (NYSE: NPTN), a leading designer and manufacturer of photonic integrated circuits, or PIC, based optoelectronic modules and subsystems for bandwidth-intensive, high speed communications networks, will report financial results for the third quarter ended September 30, 2014, after market close on Monday, November 10, 2014.
Sign-up for NeoPhotonics to Host Conference Call to Discuss Third Quarter 2014 Financial Results on Monday, November 10, 2014 investment picks
NeoPhotonics Corporation (NYSE:NPTN), a leading designer and manufacturer of hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks, today announced that management of NeoPhotonics will present at the 17 th Annual Needham Growth Conference in New York, NY on Wednesday, January 14, 2015 at 10:00 AM EST.
Sign-up for NeoPhotonics to Present at the 17th Annual Needham Growth Conference investment picks
NEW YORK and SAN DIEGO, Jan.
Sign-up for NeoStem and Invetech Announce Agreement to Develop Closed Processing System for Cell Therapy Manufacturing investment picks
NEW YORK, Nov.
Sign-up for NeoStem Announces Additions to Management investment picks
Statistically significant mortality benefit observed in patients with acute myocardial infarction (AMI) treated with intracoronary administration of CD34 cells (NBS10; AMR-001) as well as statistically significant relationship between higher cell doses and improvement in ejection fraction and reduced incidence of serious adverse events and a dose-dependent numerical decrease in major adverse cardiac events Conference call scheduled for Tuesday, November 18 th at 8:00 AM EST NEW YORK, Nov.
Sign-up for NeoStem Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical Trial investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: NEMUS Bioscience Is Now Quoted on the OTC Bulletin Board Under the Ticker Symbol of “NMUS” to NeoStem Announces USAN Approval of Generic Name 'Eltrapuldencel-T' for Investigational Patient-Specific Targeted Cancer Immunotherapy
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent